Search Result

Results for "

Tumor marker

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aldose Reductase (1) Apoptosis (2) Atg8/LC3 (1) Autophagy (1) CD38 (1) CDK (2) Cytochrome P450 (1) DNA/RNA Synthesis (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (4) Fatty Acid Synthase (FASN) (2) Fluorescent Dye (2) Hedgehog (3) Integrin (2) Isotope-Labeled Compounds (2) LAG-3 (1) MDM-2/p53 (1) Microtubule/Tubulin (1) p62 (1) Parasite (1) PD-1/PD-L1 (1) PPAR (3) Tim3 (1)
By Research Areas:	Cancer (28) Infection (1) Inflammation/Immunology (2) Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: TNF Receptor BRK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139579

Pafolacianine 1 Publications Verification OTL 38	Fluorescent Dye	Cancer
Pafolacianine (OTL 38) is a fluorescent marker made of near-infrared dye used in detecting tumor lesions during surgical procedures. Pafolacianine excites at 774 to 775 nm and emits at 794 to 796 nm .

HY-105129A

Pimonidazole 4 Publications Verification	Others	Cancer
Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor . Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia .

HY-105129

Pimonidazole hydrochloride 4 Publications Verification	Others	Cancer
Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor . Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia .

HY-D0022

5-Aminofluorescein 5-AF	Fluorescent Dye	Others
5-Aminofluorescein (5-AF) is a fluorescence marker, covalently bound to human serum albumin. The excitation wavelength is 495 nm and the emission wavelength is 535 nm .

HY-113303

FAPy-adenine	Endogenous Metabolite	Neurological Disease Cancer
FAPy-adenine is an oxidized DNA base. Fapy-adenine shows an increased trend levels in the Alzheimer's disease brain. Oxidized nucleosides are biochemical markers for tumors, aging, and neurodegenerative diseases .

HY-143889

Senexin C	CDK	Cancer
Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability .

HY-W854385

Sialyl Lewis A SLeA	Others	Cancer
Sialyl Lewis A (SLeA) is a carbohydrate-type antigen that can serve as a tumor marker, with upregulation observed in various tumor cells such as cervical cancer, human pancreatic cancer, and colon cancer cells. Sialyl Lewis A is involved in the migration and adhesion of tumor cells. Additionally, elevated expression of Sialyl Lewis A may also lead to pregnancy abnormalities .

HY-N10534

Lewis X trisaccharide Lewis X	Parasite	Infection Inflammation/Immunology Cancer
Lewis X trisaccharide (Lewis X, Le ^x) is a potent T_H2 regulator, antagonizes LPS-induced IL-12 immune expression. Lewis X trisaccharide is a human histo-blood group antigen, plays an key role in cell-cell adhesion, and servers as a tumor marker. Lewis X trisaccharide is highly expressed in the outer membrane of the parasite, can be used for the immunology research of schistosomiasis .

HY-105129AS

Pimonidazole-d10	Isotope-Labeled Compounds	Cancer
Pimonidazole-d₁₀ is the deuterium labeled Pimonidazole. Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor[1]. Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia [2].

HY-100765

BI-0252	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
BI-0252 is an orally active, selective MDM2-p53 inhibitor with an IC₅₀ of 4 nM. BI-0252 can induce tumor regressions in all animals of a mouse SJSA-1 xenograft, with concomitant induction of the tumor protein p53 (TP53) target genes and markers of apoptosis .

HY-122177

MK181	Aldose Reductase	Cancer
MK181 is an aldose reductase (AR) inhibitor with IC₅₀s of 0.71 μM and 4.5 μM for aldose reductase and AKR1B10, respectively. MK181 can bind into the external loop A subpocket of AKR1B10 .

HY-149540

CTL-06	Fatty Acid Synthase (FASN)	Cancer
CTL-06 is an inhibitor of Fatty Acid Synthase (FASN) (IC₅₀: 3 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .

HY-143432A

(S)-Cdc7-IN-18	CDK	Cancer
(S)-Cdc7-IN-18 is a potent inhibitor of CDC7. Overexpression of huCdc7 promotes overactivation of MCM2, an important marker of tumor cells, and thus promotes aberrant proliferation of tumor cells. (S)-Cdc7-IN-18 has the potential for the research of cancer diseases (extracted from patent WO2020239107A1, compound 1-1) .

HY-149541

CTL-12	Fatty Acid Synthase (FASN)	Cancer
CTL-12 is an inhibitor of fatty acid synthase (FASN) (IC₅₀: 2.5 μM) and can induce apoptosis. CTL-12 blocks the cell cycle in the Sub-G1/S phase, upregulates the expression of caspase-9 and the apoptosis marker Bax, and downregulates the anti-apoptotic marker Bcl-xL. CTL-12 inhibits de novo lipogenesis, blocks the metabolic demands of tumor cells, and is commonly used in breast and colorectal cancer research .

HY-113081

1-Methyladenosine 2 Publications Verification	Endogenous Metabolite PPAR Hedgehog	Cancer
1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-112698

CA-5f	p62 Atg8/LC3 Autophagy Apoptosis	Cancer
CA-5f is a potent late-stage macroautophagy/autophagy inhibitor via inhibiting autophagosome-lysosome fusion. CA-5f increases LC3B-II (a marker to monitor autophagy) and SQSTM1 protein, and also increases ROS production. Anti-tumor activity .

HY-144987

RBN013209	CD38 LAG-3 Tim3 PD-1/PD-L1	Inflammation/Immunology Cancer
RBN013209 is an orally active small molecule inhibitor of CD38 with an IC₅₀ of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD ⁺ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors .

HY-152159

CYP4Z1-IN-1	Cytochrome P450	Cancer
CYP4Z1-IN-1 (compound 7c) is a potent CYP4Z1 inhibitor, with an IC₅₀ of 41.8 nM. CYP4Z1-IN-1 decreases the expression of breast CSCs stemness markers, spheroid formation, and metastatic ability as well as tumor-initiation capability in a concentration-dependent manner in vitro and in vivo .

HY-113081AS

1-Methyladenosine-d3 hydrochloride	Isotope-Labeled Compounds Endogenous Metabolite PPAR Hedgehog	Cancer
1-Methyladenosine-d3 hydrochloride is the hydrochloride salt form of deuterium labeled 1-Methyladenosine (HY-113081). 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-143660

LG308	Microtubule/Tubulin Apoptosis	Cancer
LG308 is a novel synthetic compound with antimicrotubule activity. LG308 induces mitotic phase arrest and inhibits G2/M progression significantly which is associated with the upregulation of cyclin B1 and mitotic marker MPM-2 and the dephosphorylation of cdc2. LG308 also induces *apoptosis and cell death. LG308 significantly suppresses tumor* growth. LG308 with antimitotic activity has the potential for the research of prostate cancer .**

HY-P2300

Cyclo(Arg-Gly-Asp-D-Phe-Cys) Cyclo(RGDfC)	Integrin	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .

HY-P2300A

Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA Cyclo(RGDfC) TFA	Integrin	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors .

HY-118723

BMH-22	DNA/RNA Synthesis	Cancer
BMH-22, a benzonaphthyridin, is a RNA polymerase I (Pol I) transcription inhibitor independent of p53 function. BMH-22 causes reorganization of nucleolar marker proteins consistent with segregation of the nucleolus. BMH-22 destabilizes RPA194 in a proteasome-dependent manner and inhibits nascent rRNA synthesis and expression of the 45S rRNA precursor. BMH-22 shows potent anticancer activity across many tumor types .

HY-113081R

1-Methyladenosine (Standard)	Endogenous Metabolite PPAR Hedgehog	Cancer
1-Methyladenosine (Standard) is the analytical standard of 1-Methyladenosine. This product is intended for research and analytical applications. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis . In Vitro:Compared to surrounding tumor tissues, 1-methyladenosine methylation in RNA is aberrantly elevated in hepatocellular carcinoma (HCC) cell lines and liver cancer stem cells (CSCs). Methylated 1-methyladenosine can promote cholesterol synthesis and activate the Hedgehog signaling pathway by enhancing the translation of PPARδ in liver CSCs, ultimately driving the self-renewal and tumorigenesis of liver cancer stem cells .

HY-N0123

Aloin Maximum Cited Publications 7 Publications Verification Aloin-A; Barbaloin-A	Others	Cancer
Aloin (Aloin-A; Barbaloin-A) is a natural anti-tumor anthraquinone glycoside with iron chelating activity. Aloin induces the differentiation of MC3T3-E1 cells into osteoblasts through MAPK-mediated Wnt and Bmp signaling pathways. Alkaline phosphatase (ALP) is an early marker of osteoblast differentiation, and the activity of ALP is also enhanced by Aloin. Aloin also reduces brain edema, reduces blood-brain barrier disruption and improves cortical impact injuries. Aloin is used in research into osteoporosis and traumatic brain injury (TBI) .

HY-N0123R

Aloin (Standard)	Others	Cancer
Aloin (Standard) is the analytical standard of Aloin. This product is intended for research and analytical applications. Aloin (Aloin-A; Barbaloin-A) is a natural anti-tumor anthraquinone glycoside with iron chelating activity. Aloin induces the differentiation of MC3T3-E1 cells into osteoblasts through MAPK-mediated Wnt and Bmp signaling pathways. Alkaline phosphatase (ALP) is an early marker of osteoblast differentiation, and the activity of ALP is also enhanced by Aloin. Aloin also reduces brain edema, reduces blood-brain barrier disruption and improves cortical impact injuries. Aloin is used in research into osteoporosis and traumatic brain injury (TBI) .

HY-117051

STA-2842	Others	Cancer
STA-2842 is a small molecule agent that inhibits heat shock protein 90 (HSP90) to treat autosomal dominant polycystic kidney disease (ADPKD). The disease is caused by inherited mutations in the PKD1 or PKD2 genes that aberrantly activate multiple signaling proteins and pathways that regulate cell proliferation. Through network construction, we found that many HSP90 client proteins associated with ADPKD are regulated by HSP90. STA-2842 induced degradation of these clients in Pkd1?/? primary kidney cells and in vivo. In experiments using conditional Cre-mediated in vivo knockout of Pkd1 in mice, we found that weekly administration of STA-2842 for 10 weeks significantly reduced initial renal cyst formation and kidney growth in mice and slowed disease progression in mice with pre-existing cysts. These improved disease phenotypes were accompanied by improvements in renal function markers and reductions in the expression and activity of HSP90 clients and their effectors, with the extent of this inhibition correlating with the extent of cyst expansion in individual animals. Pharmacokinetic analysis showed that HSP90 was overexpressed in cystic kidney tissue and HSP90 inhibitors were selectively retained in cystic tissue, which is similar to the situation in solid tumors. These results provide a preliminary basis for evaluating HSP90 inhibitors as therapeutic agents for ADPKD.

Cat. No.	Product Name

HY-L074

Anti-Breast Cancer Compound Library	2,049 compounds
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 2,049 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Anti-Breast Cancer Compound Library

2,049 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 2,049 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Type

HY-139579

Pafolacianine 1 Publications Verification OTL 38	Fluorescent Dyes/Probes
Pafolacianine (OTL 38) is a fluorescent marker made of near-infrared dye used in detecting tumor lesions during surgical procedures. Pafolacianine excites at 774 to 775 nm and emits at 794 to 796 nm .

HY-D0022

5-Aminofluorescein 5-AF	Fluorescent Dyes/Probes
5-Aminofluorescein (5-AF) is a fluorescence marker, covalently bound to human serum albumin. The excitation wavelength is 495 nm and the emission wavelength is 535 nm .

Cat. No.	Product Name	Target	Research Area

HY-P2300

Cyclo(Arg-Gly-Asp-D-Phe-Cys) Cyclo(RGDfC)	Integrin	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors .

HY-P2300A

Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA Cyclo(RGDfC) TFA	Integrin	Cancer
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors .

HY-P4088

LyP-2	Peptides	Cancer
LyP-2 is a peptide that homes to tumor lymphatics. LyP2 homes to lymphatics of C8161 melanomas and cervical carcinomas and K14-HPV16 skin, but not to MDA-MB435 tumors, showing heterogeneity in the molecular markers of tumor cells and lymphatics .

HY-P3826

Chromogranin A (324-337), human	Peptides	Neurological Disease
Chromogranin A (324-337), human is a peptide fragment of chromogranin A, it can be isolated from human ileal carcinoid tumor. Chromogranin A is a soluble glycoprotein stored with hormones and neuropeptides in secretory granules of most (neuro)endocrine cells and neurons, and it is also a plasma marker of neuroendocrine tumors .

HY-103285

GRP (porcine) Porcine gastrin-releasing peptide 27	Peptides	Cancer
GRP (porcine) (Porcine gastrin-releasing peptide 27) is the putative mammalian analog of Bombesin (HY-P0195). GRP (porcine) activates the release of a number of gastroenteropancreatic (GEP) peptides into the peripheral circulation. GRP (porcine) stimulates gastrin release and exocrine pancreatic secretion. GRP (porcine) is a useful marker of neuroendocrine differentiation in many tumors .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113303

FAPy-adenine	Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Endogenous Metabolite
FAPy-adenine is an oxidized DNA base. Fapy-adenine shows an increased trend levels in the Alzheimer's disease brain. Oxidized nucleosides are biochemical markers for tumors, aging, and neurodegenerative diseases .

HY-113081

1-Methyladenosine 2 Publications Verification	Alkaloids Structural Classification Microorganisms Immune System Disorder Classification of Application Fields Source classification Disease markers Other Diseases Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite PPAR Hedgehog
1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-N0123

Aloin 5+ Cited Publications Aloin-A; Barbaloin-A	Quinones Structural Classification Liliaceae Classification of Application Fields Anthraquinones Source classification Phenols Polyphenols Aloe vera (L.) Burm. f. Plants Disease Research Fields Cancer	Others
Aloin (Aloin-A; Barbaloin-A) is a natural anti-tumor anthraquinone glycoside with iron chelating activity. Aloin induces the differentiation of MC3T3-E1 cells into osteoblasts through MAPK-mediated Wnt and Bmp signaling pathways. Alkaline phosphatase (ALP) is an early marker of osteoblast differentiation, and the activity of ALP is also enhanced by Aloin. Aloin also reduces brain edema, reduces blood-brain barrier disruption and improves cortical impact injuries. Aloin is used in research into osteoporosis and traumatic brain injury (TBI) .

HY-N10534

Lewis X trisaccharide Lewis X	Infection Structural Classification Natural Products Polysaccharides Animals Classification of Application Fields Inflammation/Immunology Disease Research Fields Saccharides Cancer	Parasite
Lewis X trisaccharide (Lewis X, Le ^x) is a potent T_H2 regulator, antagonizes LPS-induced IL-12 immune expression. Lewis X trisaccharide is a human histo-blood group antigen, plays an key role in cell-cell adhesion, and servers as a tumor marker. Lewis X trisaccharide is highly expressed in the outer membrane of the parasite, can be used for the immunology research of schistosomiasis .

HY-113081R

1-Methyladenosine (Standard)	Alkaloids Structural Classification Microorganisms Immune System Disorder Source classification Disease markers Endogenous metabolite Cancer	Endogenous Metabolite PPAR Hedgehog
1-Methyladenosine (Standard) is the analytical standard of 1-Methyladenosine. This product is intended for research and analytical applications. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis . In Vitro:Compared to surrounding tumor tissues, 1-methyladenosine methylation in RNA is aberrantly elevated in hepatocellular carcinoma (HCC) cell lines and liver cancer stem cells (CSCs). Methylated 1-methyladenosine can promote cholesterol synthesis and activate the Hedgehog signaling pathway by enhancing the translation of PPARδ in liver CSCs, ultimately driving the self-renewal and tumorigenesis of liver cancer stem cells .

HY-N0123R

Aloin (Standard)	Quinones Structural Classification Liliaceae Anthraquinones Source classification Phenols Polyphenols Aloe vera (L.) Burm. f. Plants	Others
Aloin (Standard) is the analytical standard of Aloin. This product is intended for research and analytical applications. Aloin (Aloin-A; Barbaloin-A) is a natural anti-tumor anthraquinone glycoside with iron chelating activity. Aloin induces the differentiation of MC3T3-E1 cells into osteoblasts through MAPK-mediated Wnt and Bmp signaling pathways. Alkaline phosphatase (ALP) is an early marker of osteoblast differentiation, and the activity of ALP is also enhanced by Aloin. Aloin also reduces brain edema, reduces blood-brain barrier disruption and improves cortical impact injuries. Aloin is used in research into osteoporosis and traumatic brain injury (TBI) .

Species:	Human (6) Mouse (2)
Tag:	His (6) Avi (1) Fc (2)
Source:	HEK293 (7) P. pastoris (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P70770

	TROP-2 Protein, Human (HEK293, His-Avi) Tumor-associated calcium signal transducer 2; Membrane component chromosome 1 surface marker 1; Cell surface glycoprotein Trop-2; TACSTD2; TROP2	Human	HEK293
	The TROP-2 protein emerged as a potential growth factor receptor, implying involvement in cellular processes related to growth and signaling. As a putative receptor, TROP-2 may play a crucial role in transducing signals that regulate cell growth and proliferation. TROP-2 Protein, Human (HEK293, His-Avi) is the recombinant human-derived TROP-2 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag. The total length of TROP-2 Protein, Human (HEK293, His-Avi) is 248 a.a., with molecular weight of 40-60 kDa.

HY-P70457

	TROP-2 Protein, Human (248a.a, HEK293, His) 1 Publications Verification Tumor-associated calcium signal transducer 2; Membrane component chromosome 1 surface marker 1; Cell surface glycoprotein Trop-2; TACSTD2; TROP2	Human	HEK293
	The TROP-2 protein emerged as a potential growth factor receptor, implying involvement in cellular processes related to growth and signaling. As a putative receptor, TROP-2 may play a crucial role in transducing signals that regulate cell growth and proliferation. TROP-2 Protein, Human (248a.a, HEK293, His) is the recombinant human-derived TROP-2 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TROP-2 Protein, Human (248a.a, HEK293, His) is 248 a.a., with molecular weight of 38-55 kDa.

HY-P70728

	TROP-2 Protein, Human (187a.a, HEK293, His) Tumor-associated calcium signal transducer 2; Membrane component chromosome 1 surface marker 1; Cell surface glycoprotein Trop-2; TACSTD2; TROP2	Human	HEK293
	The TROP-2 protein emerged as a potential growth factor receptor, implying involvement in cellular processes related to growth and signaling. As a putative receptor, TROP-2 may play a crucial role in transducing signals that regulate cell growth and proliferation. TROP-2 Protein, Human (187a.a, HEK293, His) is the recombinant human-derived TROP-2 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of TROP-2 Protein, Human (187a.a, HEK293, His) is 187 a.a., with molecular weight of 28-40 kDa.

HY-P71095

	TROP-2 Protein, Human (187a.a, HEK293, Fc) Tumor-associated calcium signal transducer 2; Membrane component chromosome 1 surface marker 1; Cell surface glycoprotein Trop-2; TACSTD2; TROP2	Human	HEK293
	The TROP-2 protein emerged as a potential growth factor receptor, implying involvement in cellular processes related to growth and signaling. As a putative receptor, TROP-2 may play a crucial role in transducing signals that regulate cell growth and proliferation. TROP-2 Protein, Human (187a.a, HEK293, Fc) is the recombinant human-derived TROP-2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of TROP-2 Protein, Human (187a.a, HEK293, Fc) is 187 a.a., with molecular weight of 60-80 kDa.

HY-P71215

	PLXDC2 Protein, Mouse (HEK293, His) Plexin domain-containing protein 2; Tumor endothelial marker 7-related protein; Plxdc2; Tem7r	Mouse	HEK293
	The PLXDC2 protein is associated with tumor angiogenesis, suggesting its potential role in blood vessel growth in the tumor microenvironment. The specific mechanism and downstream signaling pathways by which PLXDC2 promotes tumor angiogenesis need to be further elucidated, thus prompting people to explore its role in promoting vascularization during tumorigenesis. PLXDC2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived PLXDC2 protein, expressed by HEK293 , with C-6*His labeled tag. The total length of PLXDC2 Protein, Mouse (HEK293, His) is 425 a.a., with molecular weight of ~70-90 kDa.

HY-P72015

	TROP-2 Protein, Human (248a.a, HEK293, hFc) Cell surface glycoprotein Trop 2; Cell surface glycoprotein Trop-2; Cell surface glycoprotein Trop2; Epithelial glycoprotein 1; GA733 1; GA7331; M1S 1; M1S1; Membrane component chromosome 1 surface marker 1; Pancreatic carcinoma marker protein GA733 1 ; Pancreatic carcinoma marker protein GA733-1; Pancreatic carcinoma marker protein GA7331 ; TACD 2; TACD2_HUMAN; TACSTD 2; Tacstd2; Trop 2; Trop2; Tumor associated calcium signal transducer 2 precursor ; Tumor-associated calcium signal transducer 2	Human	HEK293
	The TROP-2 protein emerged as a potential growth factor receptor, implying involvement in cellular processes related to growth and signaling. As a putative receptor, TROP-2 may play a crucial role in transducing signals that regulate cell growth and proliferation. TROP-2 Protein, Human (248a.a, HEK293, hFc) is the recombinant human-derived TROP-2 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of TROP-2 Protein, Human (248a.a, HEK293, hFc) is 248 a.a..

HY-P71214

	PLXDC1 Protein, Human (HEK293, His) Plexin Domain-Containing Protein 1; Tumor Endothelial marker 3; Tumor Endothelial marker 7; PLXDC1; TEM3; TEM7	Human	HEK293
	PLXDC1 Protein, a cell surface transmembrane protein, that is also a highly expressed protein in the vascular endothelium of human tumors. Under normal and pathological conditions, PLXDC1 is involved in angiogenesis. It is expressed on the surface of tumor cells, that is highly expressed in GC cells and is likely correlated with tumor invasion and migration. The unique angiogenic function of PLXDC1 can be used in tumor anti-angiogenesis and immune research. PLXDC1 Protein, Human (HEK293, His) is the recombinant human-derived PLXDC1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P71843

	Plexin domain-containing protein 1 Protein, Mouse (P.pastoris, His) Plxdc1; Tem7; Plexin domain-containing protein 1; Tumor endothelial marker 7	Mouse	P. pastoris
	Plexin domain-containing protein 1 (PLXDC1) is critical in endothelial cell capillary morphogenesis, interacting with NID1 and possibly binding to CTTN. These interactions implicate its broader involvement in cellular responses and multiple cellular functions within the extracellular matrix. Plexin domain-containing protein 1 Protein, Mouse (P.pastoris, His) is the recombinant mouse-derived Plexin domain-containing protein 1 protein, expressed by P. pastoris , with N-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-113081AS

1-Methyladenosine-d3 hydrochloride

1-Methyladenosine-d3 hydrochloride is the hydrochloride salt form of deuterium labeled 1-Methyladenosine (HY-113081). 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis .

HY-105129AS

Pimonidazole-d10

Pimonidazole-d₁₀ is the deuterium labeled Pimonidazole. Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor[1]. Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia [2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82385

	TROP2 Antibody (YA2130) TACSTD2; GA733-1; M1S1; TROP2; Tumor-associated calcium signal transducer 2; Cell surface glycoprotein Trop-2; Membrane component chromosome 1 surface marker 1; Pancreatic carcinoma marker protein GA733-1	WB, IHC-F, IHC-P, ICC/IF	Human
	TROP2 Antibody (YA2130) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2130), targeting TROP2, with a predicted molecular weight of 36 kDa (observed band size: 45-65 kDa). TROP2 Antibody (YA2130) can be used for WB, IHC-F, IHC-P, ICC/IF experiment in human background.

HY-P81044

	MUC16 Antibody (YA890) MUC16; CA125; Mucin-16; MUC-16; Ovarian cancer-related Tumor marker CA125; CA-125; Ovarian carcinoma antigen CA125	WB, ICC/IF, IHC-P, FC	Human
	MUC16 Antibody (YA890) is an unconjugated, approximately 1519 kDa, anti-MUC16 (YA890) monoclonal antibody. MUC16 Antibody (YA890) can be used for: WB, IF-Cell, IF-Tissue, IHC-P, FC expriments in human background without labeling.

HY-P81751

	TROP2 Antibody (YA1496) TACSTD2; GA733-1; M1S1; TROP2; Tumor-associated calcium signal transducer 2; Cell surface glycoprotein Trop-2; Membrane component chromosome 1 surface marker 1; Pancreatic carcinoma marker protein GA733-1	WB, IHC-P, FC, ELISA	Human
	TROP2 Antibody (YA1496) is a mouse-derived non-conjugated IgG antibody (Clone NO.: YA1496), targeting TROP2. TROP2 Antibody (YA1496) can be used for WB,IHC-P,FC,ELISA experiment in human background.